Entity

Time filter

Source Type

North Chicago, IL, United States

North R.A.,University of Manchester | Jarvis M.F.,Abbvie Inc.
Molecular Pharmacology | Year: 2013

The study of P2X receptors has long been handicapped by a poverty of small-molecule tools that serve as selective agonists and antagonists. There has been progress, particularly in the past 10 years, as cell-based high-throughput screening methods were applied, together with large chemical libraries. This has delivered some drug-like molecules in several chemical classes that selectively target P2X1, P2X3, or P2X7 receptors. Some of these are, or have been, in clinical trials for rheumatoid arthritis, pain, and cough. Current preclinical research programs are studying P2X receptor involvement in pain, inflammation, osteoporosis, multiple sclerosis, spinal cord injury, and bladder dysfunction. The determination of the atomic structure of P2X receptors in closed and open (ATP-bound) states by X-ray crystallography is now allowing new approaches by molecular modeling. This is supported by a large body of previous work using mutagenesis and functional expression, and is now being supplemented by molecular dynamic simulations and in silico ligand docking. These approaches should lead to P2X receptors soon taking their place alongside other ion channel proteins as therapeutically important drug targets. Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics. Source


The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF is detrimental, are also provided.


Patent
Abbvie Inc. | Date: 2015-06-26

In accordance with the teaching described herein, systems and methods are provided for prodding secure access to a software application on a computing device. The software application may include a security framework having a set of predetermined security requirements. Prior to enabling access to the software application by a user, the computing device may, (i) verify installation of a device security configuration profile on the computing device, wherein the device security configuration profile certifies that the software application includes the set of predetermined security requirements, (ii) receive identifying information from the user via a user interface, (iii) verify the identifying information with an authentication server, and (iv) based on a successful verification of the identifying information, receive and store a security token. Access to the software application on the computing device may be provided for a specified period identified by the security token.


Patent
Abbvie Inc. | Date: 2015-01-23

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.


Patent
Abbvie Inc. | Date: 2015-01-12

The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.

Discover hidden collaborations